Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer

We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non–small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data. Patients with advanced-stage NSCLC treated wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ramalingam, Suresh S., Owonikoko, Taofeek K., Behera, Madhusmita, Subramanian, Janakiraman, Saba, Nabil F., Kono, Scott A., Gal, Anthony A., Sica, Gabriel, Harvey, R. Donald, Chen, Zhengjia, Klass, Carmen M., Shin, Dong M., Fu, Haian, Sun, Shi-yong R., Govindan, Ramaswamy, Khuri, Fadlo R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126230/
https://ncbi.nlm.nih.gov/pubmed/23407561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318282709c
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge